1. Introduction {#sec1}
===============

Clear cell renal cell carcinoma (ccRCC) is the most common subtype among renal cancer ([@bib62]) and ccRCC shows high inter individual heterogeneity ([@bib71]). Thus, it is difficult to predict survival outcomes of patients in clinical practice and design effective therapeutic strategies. Previous studies have already proposed strategies for stratification of ccRCC patients into subgroups based on different genetic and/or transcriptomic characteristics and prognoses of the patients ([@bib10]; [@bib12]; [@bib45]; [@bib76]). However, these studies failed to identify a clinically practical biomarker for classification of the patients at the personalized level or recommend targeted chemotherapy regimens for these patients.

Pyruvate kinase muscle type (*PKM*) is an enzyme that is involved in the final step of glycolysis and catalyzes the formation of ATP from ADP as phosphoenolpyruvate undergoes dephosphorylation to pyruvate. It is one of the key regulators of Warburg effect in tumors. Many studies have reported that different alternative splicing isoforms of *PKM* promote tumorigenesis ([@bib17]; [@bib19]; [@bib93]), cell proliferation ([@bib18]; [@bib36]; [@bib48]; [@bib55]; [@bib61]; [@bib94]), metastasis ([@bib89]; [@bib92]) and poor prognoses of patients ([@bib1]; [@bib83]) in different cancers. In a previous study, *PKM* isoform switch mediated by *PTBP1* was found in ccRCC ([@bib38]). Interestingly, we also found four different isoforms of *PKM* play a very important role in controlling metabolism of ccRCC ([@bib50]). We have observed that the expression level of four protein-coding transcripts of *PKM*, including ENST00000335181, which is encoding PKM2 and the most studied isoform of *PKM*, as well as ENST00000561609, ENST00000389093 and ENST00000568883 are highly associated with patients' prognoses ([@bib50]). Among them, high expression of ENST00000335181 and ENST00000561609 indicated a favorable survival while high expression of ENST00000389093 and ENST00000568883 indicated an unfavorable survival. Moreover, a number of conserved biological functions associated with the progression of ccRCC were oppositely dysregulated by these transcripts. Here, we hypothesized that different molecular subtypes among ccRCC patients can be characterized by the different expression patterns induced by these four prognostic transcripts and biomarkers that may be used in clinical practice can be identified.

Systems biology based approaches have been used in stratification of patients with different metabolic diseases and certain type of cancers for characterization of the patient subtypes ([@bib2]; [@bib6]; [@bib8]; [@bib9]; [@bib58]). Previous studies have also proposed transcriptomics-based biomarkers for classification of tumors based on the quantitative measurement of one or multiple signature genes ([@bib30]; [@bib40]; [@bib44]; [@bib45]; [@bib97]). However, this kind of transcriptional signatures are rarely used in clinical practice due to technological and translational barriers ([@bib86]). Besides problems in tissue sampling and quality control, an important factor is experimental batch effect which brings high variation of gene expression induced by the different laboratory conditions and personnel ([@bib33]). To solve these problems, the use of biomarkers based on the within-sample relative expression orderings (REOs) of gene pairs has been proposed ([@bib34]; [@bib68], [@bib69]). REOs-based biomarkers are robust against batch effects, invariant to monotone data normalization ([@bib24]; [@bib84]) and poor sample preparation ([@bib15]; [@bib16]; [@bib52]).

In this study, we used the genes dysregulated by the prognostic transcripts of *PKM* to extract classification biomarker instead of using themselves. Since different transcripts of *PKM* share similar sequence, it may be difficult to design distinct primers to detect their relative abundance when using real-time PCR. Thus, gene pair biomarker is more feasible and practical in clinical diagnosis. We applied REOs-based method to identify biomarkers for classification of ccRCC by extracting the expression profiles of genes which were consistently negatively dysregulated by the four favorable and unfavorable prognostic transcripts of *PKM*. We developed a REOs-based biomarker using the global gene expression profiling of ccRCC in The Cancer Genome Atlas (TCGA) database and stratified the patients into two subtypes exhibiting different transcriptomic expression patterns and different patient prognosis. We also validated our findings in TCGA database as well as in another independent Japanese cohort. We finally proposed several candidate drugs that can be used in treatment of each subtype based on transcriptomic expression profiles of drug-perturbed cancer cell lines from Connectivity Map 2.0 (CMap2).

2. Result {#sec2}
=========

2.1. Identification of signature gene set associated with four prognostic transcripts of *PKM* {#sec2.1}
----------------------------------------------------------------------------------------------

In a recent study, we have found that there are molecular subtypes that could be characterized by the expression of the four different prognostic *PKM* transcripts ([@bib50]). In order to develop a REOs-based biomarker, we identified a signature gene set associated with these four transcripts based on the gene expression profiles of TCGA ccRCC samples. We performed differential expression analysis between the tumor samples from patients with high (top 25%) and low (bottom 25%) expression of each favorable transcript, and identified 2,010 consistently significantly (FDR \<1.0e-5) differentially expressed genes (DEGs) for the two favorable transcripts ([Figure 1](#fig1){ref-type="fig"}). Similarly, we identified 5,469 DEGs consistently significantly (FDR \<1.0e-5) DEGs for the two unfavorable transcripts. We found that the two sets of DEGs has a significant overlap (n = 1,135; hypergeometric distribution test, p \< 1.11e-16). We also observed that the concordance score of these overlapped genes is 100%, which means the up-regulated genes associated with high expression of favorable transcripts within these 1,135 genes are all down-regulated when the unfavorable transcripts exhibit high expression; and vice versa.Figure 1The flowchart for developing and validating the ccRCC classification biomarker. In brief, we extract the 1135 overlapped DEGs associated with favorable and unfavorable transcripts, and select 539 prognostic signature genes from them. Next, we screen gene pair biomarker using randomly generated training dataset. Lastly, we validate the performance of the biomarker in all randomly generated validation dataset and an independent Japanese ccRCC dataset.Figure 1

We followed-up survival information from the corresponding patients and found that 539 of the 1,135 genes (of which 305 and 234 are favorable and unfavorable, respectively) are significantly (univariate Cox model, FDR \<0.01) associated with patients' overall survival (OS). To identify the associated biological functions with these 539 genes, we performed GO term enrichment analysis and observed that these genes are significantly enriched in RNA splicing, RNA catabolic process and nuclear transport pathways (FDR\<0.05; Table S1). Therefore, we concluded that these 539 genes may be used as the core signature genes that are associated with the differential alternative splicing of *PKM* among ccRCC patients and may be used for classification of tumor samples.

We calculated the co-expression coefficients between the expression of the 539 signature genes and found two major clusters in which all favorable genes are positively co-expressed while all unfavorable genes are negatively co-expressed in the opposite cluster using the hierarchical clustering ([Figure 2](#fig2){ref-type="fig"}A). Based on the expression profiles of these 539 signature genes, we employed consensus clustering to classify TCGA ccRCC samples into distinct stable sub-groups through repeated subsampling and clustering ([@bib85]). As shown in [Figure 2](#fig2){ref-type="fig"}B, we determined an optimum number of two clusters, cluster 1 and 2, based on the lowest proportion of ambiguous clustering ([@bib73]). Using survival analysis, we observed the patients whose tumor samples classified in cluster 1 (N = 231) had significantly shorter OS than those classified in cluster 2 (N = 297) with statistical significance (log-rank test, P = 6.73e-07; [Figure 2](#fig2){ref-type="fig"}C). The results demonstrated that there are two different molecular subtypes in ccRCC with significantly different survival outcomes which are strongly associated with the function of the two favorable and two unfavorable transcripts.Figure 2Molecular classification and prognostic prediction of patients by classification biomarker. (A) Hierarchical clustering of 539 signature genes based on the correlation between genes. The spearman correlation coefficients between genes were used for clustering. (B) Consensus clustering for TCGA ccRCC patients based on the expression values of the 539 signature genes. (C) Kaplan-Meier plot of OS of two clusters identified by consensus clustering in TCGA ccRCC cohort. (D) The composition of classification biomarker and voting rule. (E) Kaplan-Meier plot of OS of high- and low-risk identified by classification biomarker in TCGA ccRCC cohort. (F) Kaplan-Meier plot of OS of high- and low-risk identified by classification biomarker in Japanese ccRCC cohort.Figure 2

2.2. Development of the REOs-based classification biomarker {#sec2.2}
-----------------------------------------------------------

To identify a biomarker that can be used in the clinical practice, we next focused on development of a REOs-based classification biomarker based on the gene expression profiles of the 539 signature genes. In brief, REOs-based biomarkers employs gene pairs with consistently reversed expression orders between the two molecular groups as indicators, and screens for a minimum combination of these gene pairs that serves as risk indicators for classification. In order to obtain a robust biomarker, we generated 100 training and 100 validation datasets by randomly selecting from TCGA ccRCC cohort and randomly separated the samples into two respective groups with 70% and 30% samples. We identified 171 gene pairs that exhibited consistent reverse gene pairs in all training datasets. We next generated 17,100 reverse gene pair combinations with a forward selection procedure and selected a final REOs-based biomarker consisted of eight reverse gene pairs with an optimal mean F-score of 0.9725 in all training datasets ([Figure 2](#fig2){ref-type="fig"}D). The full screening process are shown in [Figure 1](#fig1){ref-type="fig"} and detailed in Method section.

Within this eight gene pairs, if more than four gene pairs exhibited reversal REOs in a sample, this sample would be classified into the high-risk group; otherwise, this sample would be classified into the low-risk group ([Figure 2](#fig2){ref-type="fig"}D). We tested these gene pairs in the 100 validation datasets, and found that these gene pairs also showed a good classification accuracy with a mean F-score 0.9742. We also tested these gene pairs using the complete TCGA cohort, and this biomarker classified 231 samples into high-risk group and 297 samples into low-risk group. Notably, these two groups showed significantly different OS ([Figure 2](#fig2){ref-type="fig"}E; log rank test, P = 1.69e-07).

2.3. Validation of the REOs-based classification biomarker {#sec2.3}
----------------------------------------------------------

To validate if these gene pairs can be used as a biomarker for classification of ccRCC samples, we tested these gene pairs in 100 ccRCC samples obtained from an independent Japanese cohort. The biomarker classified 35 samples as high-risk group and 65 samples as low-risk group, and these two groups showed significantly different OS ([Figure 2](#fig2){ref-type="fig"}F, P = 7.46e-05). We next investigated whether the high and low-risk groups identified in both TCGA and Japanese cohorts exhibited similar biological differences. We extracted the top 20% most significant DEGs (n = 2,694) between high and low-risk groups in both the TCGA and Japanese cohorts, and observed a significant overlap between them (*n* = 1,463; hypergeometric distribution test, *p* \< 1.11e-16) with a concordance score 100%. In addition, we identified 66 and 80 GO terms that are significantly enriched with upregulated genes (FDR\<1.0e-05) in the high-risk group of the TCGA and Japanese cohorts, respectively, and found that 55 of them are common in both cohorts ([Figure 3](#fig3){ref-type="fig"}). Specifically, the high-risk group was characterized by upregulated genes involved in ATP synthesis, mitochondrial respiratory process, oxidative phosphorylation, ribonucleotide and purine nucleotide metabolic process, RNA catabolic process, protein targeting to ER and membrane pathways. And the low-risk group was characterized by upregulated genes involved in histone modification and covalent chromatin modification pathways. The results suggested the molecular subtypes identified by our analysis also have consistent biological differences. Moreover, these 55 GO terms included all 27 GO terms that we recently reported to be associated with the four different prognostic transcripts in pan cancer analysis ([@bib50]). We also identified three GO terms that are significantly enriched with downregulated genes in the high-risk group for both cohorts, and two of them, which are the histone modification and covalent chromatin modification pathways, are common in both groups. These results further indicated that the molecular subtypes stratified by the gene pairs are functionally related to the four prognostic transcripts of *PKM.*Figure 3The dysregulated biological functions in high- and low-risk ccRCC groups and. Heat map of the p values (on the negative log 10 scale) for the enriched GO terms in TCGA and Japanese KIRC cohort. Red color denotes the GO terms enriched with up-regulated genes. Blue color denotes the GO terms enriched with down-regulated genes. \* FDR\<1.0e-05.Figure 3

Further, we compared our REOs-based classification with previously reported TCGA (m1 to m4) and ccA/ccB classification schemes ([@bib10]; [@bib12]) ([Figure 4](#fig4){ref-type="fig"}). In TCGA cohort, approximately 96% of TCGA m1 tumors were involved in our low-risk group, and m1 group was also reported with the best prognoses in TCGA classification scheme. In addition, 73% of TCGA tumors in both m2 and m4 subtypes were involved in our high-risk groups, and they were also shown to be with the poorest prognoses in TCGA classification. These results demonstrated that the high and low-risk groups classified by our biomarker are reinforced by the previously observed survival outcomes m1, m2 and m4. Notably, the high and low-risk groups respectively accounted for 42% and 58% of tumors previously reported as unclassified (m3) in the TCGA classification scheme. In Japanese cohort, 71% of ccA and 80% of ccB were observed in the low and high-risk groups, respectively. We found that the favorable survival for ccA cases again reinforced the low-risk group classification based on our gene pairs used as a biomarker ([Figure 4](#fig4){ref-type="fig"}).Figure 4Pie charts showing the intersection of the different classification schemes for ccRCC. 'm1', 'm2', 'm3' and 'm4' indicate the molecular subtypes proposed by TCGA, and 'ccA' and 'ccB' are molecular subtypes reported by another previous study.Figure 4

2.4. Drug repositioning for treatment of ccRCC subtypes {#sec2.4}
-------------------------------------------------------

In addition to classification of the tumors, we also performed drug repositioning analysis to identify drug candidates that can be used in treatment of each subtype ([Figure 5](#fig5){ref-type="fig"}). We assumed that if a drug could reverse the dysregulated gene expression pattern from a tumor subtype to normal pattern, it could be potentially useful for treating the specific tumor subtype. We used a method developed in our previous study for drug repurposing ([@bib81], [@bib80], [@bib82]) and found several drugs that could be used for treatment of the high and low-risk groups (see Method). We found that four different drugs including paracetamol, nizatidine, dimethadione and conessine may be used to reverse the gene expression in samples from high-risk group, since over 80% drug-perturbed genes were mapped to the DEGs between these samples and normal samples. Paracetamol is an analgesic and antipyretic drug with the effect of anti-inflammatory and inhibits the production of multiple oxidants ([@bib32]). Interestingly, it has been reported that paracetamol inhibits the cell proliferation and induces cell apoptosis in pancreatic cancer ([@bib57]), ovarian cancer and lung cancer cells ([@bib51]). Nizatidine is an antagonist of histamine H~2~ receptors and these receptors are associated with cell proliferation, embryonic development and tumor growth ([@bib27]). It has been shown that nizatidine was recommended to be added into the combination therapy for cancer treatment ([@bib4]; [@bib5]; [@bib26]). Conessine, a steroid alkaloid, decreases basal NF-κB activity, regulates autophagy, has anti-inflammatory effect ([@bib42], [@bib41]) and is proposed as a potential anti-cancer drug. Therefore, the anti-cancer effects of three of the proposed drugs have been reported in previous studies.Figure 5The flowchart for drug repositioning.Figure 5

Similarly, we found that three different drugs including chenodeoxycholic acid, fenoterol and hexylcaine, may be used to reverse the gene expression in samples of low-risk group towards normal samples. It has been reported that natural as well as synthetic bile acids can modulate cell cycle and induce apoptosis in cancer cells ([@bib35]; [@bib43]). Chenodeoxycholic acid, a bile acid, shows anti-proliferative activity in human cancer cells ([@bib25]). Beta-adrenergic signaling pathway has been found to promote the initiation and progression of cancer including inflammation, angiogenesis, apoptosis, cell motility, DNA damage repair and epithelial-mesenchymal transition ([@bib21]). Fenoterol, a beta-adrenoreceptor agonist, has been shown to inhibit the proliferation of glioblastomas and astrocytomas cells ([@bib7]; [@bib78]). Hexylcaine, a short-acting local anesthetic, has also been used to treat cancer ([@bib31]) even its anti-cancer activity is still unclear. In this context, these three drugs may also be potentially used for treatment of the subtype of ccRCC patients.

Moreover, we identified the gene targets for each of the drugs using DrugBank database ([@bib87]). *HRH2*, encoding the histamine H~2~ receptor, has been reported as the gene target of nizatidine ([@bib60]). We observed that it is significantly up-regulated in the samples of high-risk group compared to normal samples. It has been demonstrated that in vitro and in vivo histamine-induced tumor cell proliferation can be blocked by H~2~ antagonists ([@bib23]; [@bib63]; [@bib79]). Thus, nizatidine may be used as a promising drug for the patients classified in the high-risk group. On the other hand, *GPBAR1*, encoding an enzyme of the G protein-coupled receptor superfamily, has been reported as a target of chenodeoxycholic acid. It has been shown that *GPBAR1* antagonizes kidney cancer cell proliferation and migration ([@bib75]). Based on our analysis, we have observed that *GPBAR1* is significantly downregulated in the low-risk group compared to normal samples. Thus, chenodeoxycholic acid, as an activator of *GPBAR1*, may be used as a promising drug for treating the patients classified in the low-risk group.

3. Discussion {#sec3}
=============

*PKM* is one of the important regulators of Warburg effect in different human cancers ([@bib22]). Our recent study showed that four different transcripts of *PKM* mediate opposite survival outcomes for ccRCC patients. In this study, we identified the core signature genes which were consistently dysregulated by these four prognostic transcripts of *PKM*. Using these signature genes, we identified eight gene pairs whose within-samples REOs could be used to classify patients into two groups with significantly different OS. Although RNA sequencing data was used for the biomarker classification in this study, much cheaper technics could be used once the biomarker is used in clinical practice. For instance, we could use real-time PCR, which is much cheaper compared to the sequencing approach, to determine the relative abundance of the genes involved in these 8 gene pairs to classify a ccRCC tumor sample since we only need to detect their REOs.

Real-time PCR has been used for commercial mRNA-based gene signatures. One FDA-approved signature is AlloMap®, consisting of 20 genes, for estimating the risk of acute cellular rejection in heart transplant recipients ([@bib74]). Another FDA-approved signature is Oncotype DX®, consisting 21 genes, for estimating the risk of distant recurrence in tamoxifen-treated patients with node-negative, estrogen-receptor-positive breast cancer ([@bib65]). Both of the signatures used in classification of patients into different risk groups by comparing their risk scores summarized from expression levels of the signature genes with preset risk score thresholds. However, the preset thresholds from the training dataset cannot be directly applied to independent dataset since the gene expression levels are sensitive to batch effects and platform differences ([@bib68]). To solve this problem, the tissue samples must be sent to the specified laboratories for measurement with uniform quality control and data normalization, which brings great limitations for wide application of these signatures. In contrast, the relative abundance of two genes in a gene pair is much easier to be estimated by real-time PCR with appropriate performance since REOs-based biomarkers are relatively insensitive to both experimental and bioinformatics variations, which could greatly facilitate the use of REOs-based biomarker in clinical practice.

The genes involved in our classification of ccRCC tumor samples also showed closed relationship with tumor development. For instance, *RP9*, one of genes in the REOs gene pairs, plays an important role in pre-mRNA splicing and could interact with well-known oncogene *PIM-1* ([@bib56]). *MYO9A*, encodes an unconventional myosin, which is required for collective migration of epithelial cells and thus serves as a potent promoter in progression and metastasis of cancers of epithelial origin ([@bib29]; [@bib64]). *TAZ* encodes tafazzin whose overexpression promotes tumorigenicity in many cancers and its inhibition also induces tumor cell apoptosis ([@bib14]; [@bib49]; [@bib66]). *GADD45GIP1*, also known as *CRIF1*, encodes a nuclear-localized protein that may be induced by *TP53* and regulates cell cycle. *CRIF1* is a novel transcriptional coactivator of *STAT3* which is a well-known oncogene in multiple human cancers ([@bib47]). However, *CRIF1* was recruited to the upstream promoter region of *TP53* to suppress cell cycle progression in HCT116 cells ([@bib90]). Thus, the role of *CRIF1* is controversial in cancer. *SNRNP200* encodes a component of U5 snRNP-specific proteins of spliceosome. It has been shown that overexpression of *SNRNP200* was associated with tumor aggressiveness in prostate cancer ([@bib39]). *PIK3CB* is involved in the PI3K signaling pathway which is frequently dysregulated in cancer. Inhibition of *PIK3CB* remarkably suppressed cell growth, migration and enhanced apoptosis in glioblastoma ([@bib13]; [@bib67]). *NOLC1* functions as a chaperone for shuttling between the nucleolus and cytoplasm ([@bib59]). It has been reported that enhancement of *NOLC1* promotes cell senescence and represses hepatocellular carcinoma cell proliferation by disturbing the organization of nucleolus ([@bib96]).

The immunotherapy is widely used in ccRCC since the disturbance of different immunological pathways were observed in ccRCC ([@bib53]). In this study, we found some of our biomarker genes are potential targets for immunotherapy. *TAZ* also acts as a regulator in immune evasion of cancer by positively modulating the expression of *PD-L1* in mRNA and protein level ([@bib37]), which is a potential maker for immunotherapy. In our analysis, both *TAZ* and *PD-L1* are significantly highly expressed in high- or low-risk samples compared with normal samples. Especially, the expression of *TAZ* is much higher in high-risk patients than low-risk patients, suggesting that targeting *TAZ* is a more promising treatment strategy for high-risk patients besides *PD-L1* immunotherapy. *MYO9A* is highly expressed in immune cells and plays an important role in regulation of macrophage shape and motility ([@bib3]). In our analysis, *MYO9A* was significantly down-regulated in high-risk samples compared with low-risk and normal samples, suggesting the innate immune response may be weak in high-risk ccRCC patients. *IBTK* encodes the inhibitor of Bruton tyrosine kinase which is required for B cell survival, differentiation and activation ([@bib28]). In our analysis, the expression of *IBTK* was increasingly down-regulated in normal, low-risk and high-risk samples, suggesting that B cell immune system is active in ccRCC. *NBR1* encodes a specific autophagy receptor. It has been reported that NBR1-deficient mice have defective T helper 2 cell differentiation ([@bib91]). The histone methyltransferase *ASH1L* is involved in the regulation of regulatory T cell polarization ([@bib88]). In our analysis, both the expression of *NBR1* and *ASH1L* were increasingly down-regulated in normal, low-risk and high-risk samples, suggesting that T cell immune system may be impaired in ccRCC. *PIK3CB* is critical in neutrophil activation by immune complexes ([@bib46]), which is significantly down-regulated in the high-risk samples compared to low-risk and normal samples.

In conclusion, we identified two molecular subtypes of ccRCC patients with high and low-risk of mortality, and developed a REOs-based classification biomarker which could be used to classify the ccRCC patients into these subtypes at personalized level. In addition, we suggested specific treatment strategies for each subtype based on their global gene expression patterns and drug repositioning. Therefore, it is worthwhile to further explore the potential clinical use of the here identified biomarker in assisting clinical diagnosis and treatment of ccRCC patients.

4. Materials and methods {#sec4}
========================

4.1. Data and preprocessing {#sec4.1}
---------------------------

The TCGA transcript-expression level profiles (TPM and count values) of ccRCC and matched normal kidney samples was downloaded from <https://osf.io/gqrz9> ([@bib77]) on November 27, 2018, which was quantified by Kallisto ([@bib11]) based on the GENCODE reference transcriptome (version 24). The clinical information of TCGA samples was downloaded through R package TCGAbiolinks ([@bib20]). The whole-exome sequence data of 100 ccRCC samples of patients from Japanese cohort ([@bib72]) was downloaded from European Genome-phenome Archive (accession number: EGAS00001000509). BEDTools ([@bib70]) was used for converting BAM to FASTQ file. Kallisto was used for estimating the count and TPM values of transcripts based on the same reference transcriptome of TCGA data. The sum value of the multiple transcripts of a gene was used as the expression value of this gene. The genes with average TPM values \> 1 in ccRCC patients were analyzed.

4.2. Differential expression analysis {#sec4.2}
-------------------------------------

DESeq2 ([@bib54]) was used to identify DEGs between two groups. The raw count values of genes were used as input of DESeq2. The Benjamini-Hochberg (BH) procedure was used to estimate FDR.

4.3. Overlapping of two lists of DEGs {#sec4.3}
-------------------------------------

If DEG list 1 with *L*~*1*~ genes and DEG list 2 with *L*~*2*~ genes have *k* overlapping genes and *s* of these genes shows the same directions which means high expression of these genes indicates favorable/unfavorable survival or group 1/2 in both lists, the probability of observing at least *s* consistent genes by chance can be calculated according to the following cumulative hypergeometric distribution model:$$\text{P} = 1 - \sum\limits_{i = 0}^{s - 1}\frac{\begin{pmatrix}
{L2} \\
i \\
\end{pmatrix}\begin{pmatrix}
{L - L2} \\
{L1 - i} \\
\end{pmatrix}}{\begin{pmatrix}
L \\
{L1} \\
\end{pmatrix}}$$where *L* represents the number of the background genes commonly detected in the datasets from which the DEGs are extracted. The two DEG lists were considered to be significantly overlapping if P \< 0.05.

The concordance score *s*/*k* is used to evaluate the consistency of DEGs between the two lists. Obviously, the score ranges from 0 to 1, and the higher concordance score suggests the better consistency of two lists of DEGs.

4.4. Consensus clustering {#sec4.4}
-------------------------

Consensus clustering ([@bib85]) was used for tumor classification based on the normalized expression profiles of signature genes by Z-score transformation. To achieve robust clusters, the data was resampled for 1000 times by considering 80% samples and signature genes resampling. The resampled data was transformed into a similarity matrix, termed as consensus matrix. K-means clustering was used to stratify samples based on the consensus matrix. The number of optimum cluster was determined by the lowest proportion of ambiguous clustering.

4.5. Survival analysis {#sec4.5}
----------------------

The univariate Cox regression model was used to evaluate the correlation of gene expression levels with OS. Survival curves were estimated by the Kaplan-Meier method and compared with the log-rank test.

4.6. Functional enrichment analysis {#sec4.6}
-----------------------------------

GO enrichment was performed by the enrichGo function in R package ClusterProfiler ([@bib95]), in which the hypergeometric distribution was used to calculate the statistical significance of biological pathways enriched with DEGs of interest.

4.7. Development of the REOs-based biomarker {#sec4.7}
--------------------------------------------

In each sample, the REO of every two signature genes (i and j) is denoted as either G~i~ \> G~j~ or G~i~ \< G~j~ exclusively, where G~i~ and G~j~ represent the expression values of gene i and j, respectively. For a given gene pair (G~i~ and G~j~), we used Fisher\'s exact test to evaluate whether the frequency of group 1 samples with a specific REO pattern (G~i~ \> G~j~ or G~i~ \< G~j~) was significantly different from that in group 2 samples in each training dataset. The P values are adjusted using BH procedure. The gene pairs detected with 0.05 FDR control and over 70% difference of the frequency of their REOs between two groups were denoted as reversed gene pairs. The overlapped reversed gene pairs consistently identified from all the training datasets were selected as the candidate signature gene pairs. Totally, we found 171 signature gene pairs. For each signature gene pair, according to their within-sample REO, we classified the samples of each training dataset into high or low-risk groups and then evaluated the sensitivity and specificity of this gene pair. Here, the sensitivity is defined as the ratio of correctly identified high risk samples to all high-risk samples and the specificity is defined as the ratio of correctly identified low-risk samples to all low-risk samples. Then, from these signature gene pairs, we performed a forward selection procedure in each training dataset to search a set of gene pairs that achieved the highest F-score value, a harmonic mean of sensitivity and specificity, which is calculated as follows:$$F - score = \frac{2\left( \text{sensitivity*specificity} \right)}{\left( {\text{sensitivity} + \text{specificity}} \right)}$$

Taking each of the 171 gene pairs as a seed, we added another gene pair to the biomarker at a time until the F-score did not increase. The classification rule is that a sample is classified into high or low-risk group if the majority of the REOs of the set of gene pairs within this sample vote for high or low-risk. We got 171 biomarkers based on each training dataset. Totally, we got 17,100 candidate biomarkers for all the 100 training datasets. Finally, we selected the biomarker with the lowest (1-F~1~)^2^+(1-F~2~)^2^+∙∙∙+(1-F~n~)^2^ as the final biomarker, in which F~n~ is the F-score value in the n^th^ training dataset.

4.8. Application of CMap2 data to drug discovery {#sec4.8}
------------------------------------------------

The pre-procession of CMap2 data was described in our previous study ([@bib82]). In brief, the gene expression profiles of three cell lines, HL60, MCF2 and PC3, were downloaded from <https://portals>. broadinstitute.org/cmap/(CMap Build 02). As shown in [Figure 5](#fig5){ref-type="fig"}, a single treatment cell line and control were selected to calculate Log2FC of genes by comparison between the two cases for each cell line. We normalized the log2FC matrix with 12,228 genes and 683 drugs to z-score matrix and further transformed it to P value matrix. Then, the confidence score was calculated per each drug-gene interaction using the P values from three cell lines. An approximation confidence score to 1 was assumed as the higher confidence level. The drug-gene pairs with CS \> 0.5 were used in further analysis. If over 80% drug-perturbed genes with CS \> 0.5 were mapped to the DEGs between one subtype of cancer samples and normal samples, this drug is considered to have reverse effect on the dysregulated gene expression in this subtype of cancer samples.
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